Healius Ltd (HLS)

Currency in AUD
0.840
+0.040(+5.00%)
Closed·
HLS Scorecard
Full Analysis
Significant return over the last week
High dividend Yield
HLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8080.850
52 wk Range
0.6951.860
Key Statistics
Bid/Ask
0.835 / 0.85
Prev. Close
0.8
Open
0.81
Day's Range
0.808-0.85
52 wk Range
0.695-1.86
Volume
9.02M
Average Volume (3m)
5.35M
1-Year Change
-41.2%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.989
Upside
+17.72%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Healius Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Healius Ltd Company Profile

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories, medical centers, patient collection centers, and community imaging centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Compare HLS to Peers and Sector

Metrics to compare
HLS
Peers
Sector
Relationship
P/E Ratio
−19.1x26.1x−0.5x
PEG Ratio
−0.19−0.100.00
Price/Book
0.6x1.8x2.6x
Price / LTM Sales
0.3x1.4x3.3x
Upside (Analyst Target)
5.0%13.3%43.5%
Fair Value Upside
Unlock7.2%6.9%Unlock

Analyst Ratings

1 Buy
6 Hold
5 Sell
Ratings:
12 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.989
(+17.72% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.04%
Dividend Yield
49.17%
Industry Median 3.08%
Annualised payout
0.41
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

HLS Income Statement

People Also Watch

2.56
NUF
-1.54%
2.840
CWY
-0.70%
1.770
PLS
+3.81%
2.11
ORA
+0.96%
214.480
MQG
-0.81%

FAQ

What Stock Exchange Does Primary Health Care Trade On?

Primary Health Care is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Primary Health Care?

The stock symbol for Primary Health Care is "HLS."

What Is the Primary Health Care Market Cap?

As of today, Primary Health Care market cap is 609.95M.

What Is Primary Health Care's Earnings Per Share (TTM)?

The Primary Health Care EPS (TTM) is -0.04.

When Is the Next Primary Health Care Earnings Date?

Primary Health Care will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is HLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Primary Health Care Stock Split?

Primary Health Care has split 2 times.

How Many Employees Does Primary Health Care Have?

Primary Health Care has 6994 employees.

What is the current trading status of Primary Health Care (HLS)?

As of 07 Aug 2025, Primary Health Care (HLS) is trading at a price of 0.84, with a previous close of 0.80. The stock has fluctuated within a day range of 0.81 to 0.85, while its 52-week range spans from 0.70 to 1.86.

What Is Primary Health Care (HLS) Price Target According to Analysts?

The average 12-month price target for Primary Health Care is AUD0.98886, with a high estimate of AUD1.8 and a low estimate of AUD0.7. 1 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Neutral. The stock has an +17.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.